US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% MSTR $160.01 ▲+0.00% ASML $1,867.31 ▲+0.00%
FinancialContent

Articles published by AtaiBeckley N.V.

News headline image
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley To Participate in Upcoming Investor Conferences
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Completes Redomiciliation to the United States
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
From AtaiBeckley N.V.
Via GlobeNewswire
Tickers ATAI